These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17764832)

  • 1. Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines.
    Ohsugi T; Kumasaka T; Okada S; Ishida T; Yamaguchi K; Horie R; Watanabe T; Umezawa K
    Cancer Lett; 2007 Nov; 257(2):206-15. PubMed ID: 17764832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia.
    Ohsugi T; Horie R; Kumasaka T; Ishida A; Ishida T; Yamaguchi K; Watanabe T; Umezawa K; Urano T
    Carcinogenesis; 2005 Aug; 26(8):1382-8. PubMed ID: 15831528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
    Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
    Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antitumor activity of the NF-kappaB inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102.
    Ohsugi T; Kumasaka T; Ishida A; Ishida T; Horie R; Watanabe T; Umezawa K; Yamaguchi K
    Leuk Res; 2006 Jan; 30(1):90-7. PubMed ID: 16002138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia.
    Watanabe M; Ohsugi T; Shoda M; Ishida T; Aizawa S; Maruyama-Nagai M; Utsunomiya A; Koga S; Yamada Y; Kamihira S; Okayama A; Kikuchi H; Uozumi K; Yamaguchi K; Higashihara M; Umezawa K; Watanabe T; Horie R
    Blood; 2005 Oct; 106(7):2462-71. PubMed ID: 15956280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma.
    Horie R; Watanabe T; Umezawa K
    Drug News Perspect; 2006 May; 19(4):201-9. PubMed ID: 16823495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
    Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
    Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
    Wakamatsu K; Nanki T; Miyasaka N; Umezawa K; Kubota T
    Arthritis Res Ther; 2005; 7(6):R1348-59. PubMed ID: 16277688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
    Poma P; Notarbartolo M; Labbozzetta M; Sanguedolce R; Alaimo A; Carina V; Maurici A; Cusimano A; Cervello M; D'Alessandro N
    Int J Oncol; 2006 Apr; 28(4):923-30. PubMed ID: 16525642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NF-kappaB in pathogenesis and treatment of adult T-cell leukemia/lymphoma.
    Horie R
    Int Rev Immunol; 2007; 26(5-6):269-81. PubMed ID: 18027201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
    Ruan HY; Masuda M; Ito A; Umezawa K; Nakashima T; Yasumatsu R; Kuratomi Y; Yamamoto T; Weinstein IB; Komune S
    Head Neck; 2006 Feb; 28(2):158-65. PubMed ID: 16355386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Ueki S; Yamashita K; Aoyagi T; Haga S; Suzuki T; Itoh T; Taniguchi M; Shimamura T; Furukawa H; Ozaki M; Umezawa K; Todo S
    Transplantation; 2006 Dec; 82(12):1720-7. PubMed ID: 17198266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
    Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
    Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
    Kimura N; Miyakawa Y; Kohmura K; Umezawa K; Ikeda Y; Kizaki M
    Leuk Res; 2007 Nov; 31(11):1529-35. PubMed ID: 17466373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
    Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ).
    Horiuchi K; Morioka H; Nishimoto K; Suzuki Y; Susa M; Nakayama R; Kawai A; Sonobe H; Takaishi H; Ozaki T; Yabe H; Umezawa K; Toyama Y
    Cancer Lett; 2008 Dec; 272(2):336-44. PubMed ID: 18760530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.
    Kodaira K; Kikuchi E; Kosugi M; Horiguchi Y; Matsumoto K; Kanai K; Suzuki E; Miyajima A; Nakagawa K; Tachibana M; Umezawa K; Oya M
    Urology; 2010 Apr; 75(4):805-12. PubMed ID: 20156648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion.
    Mino K; Ozaki M; Nakanishi K; Haga S; Sato M; Kina M; Takahashi M; Takahashi N; Kataoka A; Yanagihara K; Ochiya T; Kamiyama T; Umezawa K; Todo S
    Cancer Sci; 2011 May; 102(5):1052-8. PubMed ID: 21288284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Suzuki E; Umezawa K
    Biomed Pharmacother; 2006 Nov; 60(9):578-86. PubMed ID: 16978829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.